Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895782973> ?p ?o ?g. }
- W2895782973 endingPage "G18" @default.
- W2895782973 startingPage "G1" @default.
- W2895782973 abstract "The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing primarily on methods for screening, management and monitoring for endocrine side effects in patients treated by ICPI. We will then look in turn at endocrinopathies that are induced by ICPI including dysthyroidism, hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter, expert opinion will be given on the diagnosis, management and monitoring for each complication. These expert opinions will also discuss the methodology for categorizing these side effects in oncology using ‘common terminology criteria for adverse events’ (CTCAE) and the difficulties in applying this to endocrine side effects in the case of these anti-cancer therapies. This is shown in particular by certain recommendations that are used for other side effects (high-dose corticosteroids, contraindicated in ICPI for example) and that cannot be considered as appropriate in the management of endocrine toxicity, as it usually does not require ICPI withdrawal or high-dose glucocorticoid intake." @default.
- W2895782973 created "2018-10-26" @default.
- W2895782973 creator A5003323204 @default.
- W2895782973 creator A5004138398 @default.
- W2895782973 creator A5006673441 @default.
- W2895782973 creator A5007224930 @default.
- W2895782973 creator A5008529320 @default.
- W2895782973 creator A5009182471 @default.
- W2895782973 creator A5010322165 @default.
- W2895782973 creator A5011298568 @default.
- W2895782973 creator A5015697378 @default.
- W2895782973 creator A5024262598 @default.
- W2895782973 creator A5032617675 @default.
- W2895782973 creator A5032801797 @default.
- W2895782973 creator A5037117081 @default.
- W2895782973 creator A5044089887 @default.
- W2895782973 creator A5051115285 @default.
- W2895782973 creator A5055392111 @default.
- W2895782973 creator A5056105163 @default.
- W2895782973 creator A5060383322 @default.
- W2895782973 creator A5070226523 @default.
- W2895782973 creator A5073711627 @default.
- W2895782973 creator A5077171092 @default.
- W2895782973 creator A5089346180 @default.
- W2895782973 creator A5091480628 @default.
- W2895782973 date "2019-02-01" @default.
- W2895782973 modified "2023-10-17" @default.
- W2895782973 title "French Endocrine Society Guidance on endocrine side effects of immunotherapy" @default.
- W2895782973 cites W1185432402 @default.
- W2895782973 cites W1809627231 @default.
- W2895782973 cites W1907829837 @default.
- W2895782973 cites W1979811833 @default.
- W2895782973 cites W1985110807 @default.
- W2895782973 cites W1991656907 @default.
- W2895782973 cites W2022073464 @default.
- W2895782973 cites W2028450449 @default.
- W2895782973 cites W2032060513 @default.
- W2895782973 cites W2036195858 @default.
- W2895782973 cites W2040851929 @default.
- W2895782973 cites W2056085563 @default.
- W2895782973 cites W2068611826 @default.
- W2895782973 cites W2068946981 @default.
- W2895782973 cites W2085172491 @default.
- W2895782973 cites W2085247907 @default.
- W2895782973 cites W2097995306 @default.
- W2895782973 cites W2100228832 @default.
- W2895782973 cites W2103741075 @default.
- W2895782973 cites W2104549050 @default.
- W2895782973 cites W2106511606 @default.
- W2895782973 cites W2109465910 @default.
- W2895782973 cites W2109653150 @default.
- W2895782973 cites W2115579533 @default.
- W2895782973 cites W2127446775 @default.
- W2895782973 cites W2128758225 @default.
- W2895782973 cites W2130826590 @default.
- W2895782973 cites W2131950300 @default.
- W2895782973 cites W2135738164 @default.
- W2895782973 cites W2143163879 @default.
- W2895782973 cites W2153935963 @default.
- W2895782973 cites W2156404047 @default.
- W2895782973 cites W2158840473 @default.
- W2895782973 cites W2159170430 @default.
- W2895782973 cites W2161550811 @default.
- W2895782973 cites W2164880863 @default.
- W2895782973 cites W2165456770 @default.
- W2895782973 cites W2166107256 @default.
- W2895782973 cites W2166662937 @default.
- W2895782973 cites W2166879981 @default.
- W2895782973 cites W2185075416 @default.
- W2895782973 cites W2198093519 @default.
- W2895782973 cites W2277326116 @default.
- W2895782973 cites W2289841322 @default.
- W2895782973 cites W2305396859 @default.
- W2895782973 cites W2344221521 @default.
- W2895782973 cites W2412250098 @default.
- W2895782973 cites W2512251660 @default.
- W2895782973 cites W2519279652 @default.
- W2895782973 cites W2520464001 @default.
- W2895782973 cites W2527905628 @default.
- W2895782973 cites W2533633657 @default.
- W2895782973 cites W2546981544 @default.
- W2895782973 cites W2560367415 @default.
- W2895782973 cites W2560876009 @default.
- W2895782973 cites W2561156916 @default.
- W2895782973 cites W2572174216 @default.
- W2895782973 cites W2577007969 @default.
- W2895782973 cites W2586675028 @default.
- W2895782973 cites W2588916311 @default.
- W2895782973 cites W2599354912 @default.
- W2895782973 cites W2607950543 @default.
- W2895782973 cites W2613745448 @default.
- W2895782973 cites W2635292439 @default.
- W2895782973 cites W2735117693 @default.
- W2895782973 cites W2736166064 @default.
- W2895782973 cites W2736948963 @default.
- W2895782973 cites W2743419024 @default.
- W2895782973 cites W2749679400 @default.
- W2895782973 cites W2752227448 @default.